



26 October 2020

Novartis Pharma AG
Basel, Switzerland
CH-4002

Reference: EudraCT 2011-003392-10 Novartis Protocol ID CMEK162Y2201.

An open label study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEK162 in Noonan syndrome hypertrophic cardiomyopathy.

Trial 2011-003392-10 was cancelled with no patient enrollment and as such, no results will be reported.